Metabolite to Modifier: Lactate and Lactylation in the Evolution of Tumors

Abstract

Lactate, once dismissed as a mere by-product of cancer metabolism, has emerged as a pivotal factor in tumor progression, exerting diverse effects on metabolic reprogramming and immune modulation. Lactate enhances tumor cell adaptability through sustained glycolysis and concurrently shapes the tumor microenvironment by modulating immune, stromal, and endothelial cell function. This review highlights the evolving understanding of lactate's role, extending beyond the Warburg effect to its regulatory capacity via lactylation, a recently identified post-translational modification. The complex interaction between lactate and tumor biology is examined, emphasizing its influence on the tumor microenvironment and immune dynamics. Additionally, potential therapeutic strategies targeting lactate metabolism and transport are explored, along with lactylation regulation by histone-modifying enzymes. Inhibitors targeting lactate production and transport, especially those against lactate dehydrogenase (LDH) and monocarboxylate transporters (MCTs), have shown considerable potential in preclinical and early clinical studies. Recent advancements are discussed, underscoring the potential of integrating metabolic regulation with immunotherapies, thereby offering a dual pathway in cancer treatment. These insights establish lactate and lactylation as pivotal modulators of tumor biology and highlight their potential as targets in precision oncology.

Keywords

cancer therapy / immune modulation / lactate / lactylation / metabolic reprogramming / tumor microenvironment

References

[1] B. S. Ferguson, M. J. Rogatzki, M. L. Goodwin, D. A. Kane, Z. Rightmire, and L. B. Gladden, “Lactate Metabolism: Historical Context, Prior Misinterpretations, and Current Understanding,” European Journal of Applied Physiology 118, no. 4 (2018): 691-728.

[2] C. C. Daw, K. Ramachandran, B. T. Enslow, et al., “Lactate Elicits ER-Mitochondrial Mg²⁺ Dynamics to Integrate Cellular Metabolism,” Cell 183, no. 2 (2020): 474-489.e17.

[3] Y. Zhao, M. Li, X. Yao, et al., “HCAR1/MCT1 Regulates Tumor Ferroptosis Through the Lactate-Mediated AMPK-SCD1 Activity and Its Therapeutic Implications,” Cell Reports 33, no. 10 (2020): 108487.

[4] G. A. Brooks, “Cell-Cell and Intracellular Lactate Shuttles,” Journal of Physiology 587, no. 23 (2009): 5591-5600.

[5] T. P. Brown and V. Ganapathy, “Lactate/GPR81 Signaling and Proton Motive Force in Cancer: Role in Angiogenesis, Immune Escape, Nutrition, and Warburg Phenomenon,” Pharmacology & Therapeutics 206 (2020): 107451.

[6] M. V. Liberti and J. W. Locasale, “The Warburg Effect: How Does It Benefit Cancer Cells?,” Trends in Biochemical Sciences 41, no. 3 (2016): 211-218.

[7] P. Vaupel and G. Multhoff, “Revisiting the Warburg Effect: Historical Dogma Versuscurrent Understanding,” Journal of Physiology 599, no. 6 (2021): 1745-1757.

[8] L. Li, S. Sun, Y. Wu, et al., “Lactate and Protein Lactylation: The Ugly Duckling of Energy as the Sculpture Artist of Proteins,” Science Bulletin (Beijing) 68, no. 21 (2023): 2510-2514.

[9] Z. Yang, Y. Zheng, and Q. Gao, “Lysine Lactylation in the Regulation of Tumor Biology,” Trends in Endocrinology and Metabolism: TEM 35, no. 8 (2024): 720-731.

[10] D. Zhang, Z. Tang, H. Huang, et al., “Metabolic Regulation of Gene Expression by Histone Lactylation,” Nature 574, no. 7779 (2019): 575-580.

[11] S.-M. Fendt, “100 Years of the Warburg Effect: A Cancer Metabolism Endeavor,” Cell 187, no. 15 (2024): 3824-3828.

[12] G. A. Brooks, “Lactate as a Fulcrum of Metabolism,” Redox Biology 35 (2020): 101454.

[13] N. Wang, X. Jiang, S. Zhang, et al., “Structural Basis of Human Monocarboxylate Transporter 1 Inhibition by Anti-Cancer Drug Candidates,” Cell 184, no. 2 (2021): 370-383.e13.

[14] M. Singh, J. Afonso, D. Sharma, et al., “Targeting Monocarboxylate Transporters (MCTs) in Cancer: How Close Are We to the Clinics?,” Seminars in Cancer Biology 90 (2023): 1-14.

[15] S. D'Aria, C. Maquet, S. Li, et al., “Expression of the Monocarboxylate Transporter MCT1 Is Required for Virus-Specific Mouse CD8(+) T Cell Memory Development,” PNAS 121, no. 13 (2024): e2306763121.

[16] X. She, Q. Wu, Z. Rao, et al., “SETDB1 Methylates MCT1 Promoting Tumor Progression by Enhancing the Lactate Shuttle,” Advanced Science (Weinh) 10, no. 28 (2023): e2301871.

[17] M. A. Felmlee, R. S. Jones, V. Rodriguez-Cruz, K. E. Follman, and M. E. Morris, “Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease,” Pharmacological Reviews 72, no. 2 (2020): 466-485.

[18] S. Ishihara, K. Hata, K. Hirose, et al., “The Lactate Sensor GPR81 Regulates Glycolysis and Tumor Growth of Breast Cancer,” Scientific Reports 12, no. 1 (2022): 6261.

[19] B. A. Webb, M. Chimenti, M. P. Jacobson, and D. L. Barber, “Dysregulated pH: A Perfect Storm for Cancer Progression,” Nature Reviews Cancer 11, no. 9 (2011): 671-677.

[20] V. M. Ngwa, D. N. Edwards, M. Philip, and J. Chen, “Microenvironmental Metabolism Regulates Antitumor Immunity,” Cancer Research 79, no. 16 (2019): 4003-4008.

[21] M. J. Watson, P. D. A. Vignali, S. J. Mullett, et al., “Metabolic Support of Tumour-Infiltrating Regulatory T Cells by Lactic Acid,” Nature 591, no. 7851 (2021): 645-651.

[22] V. Y. Tu, A. Ayari, and R. S. O'Connor, “Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies Against Cancer,” Antibodies 10, no. 3 (2021): 25.

[23] A. Angelin, L. Gil-De-Gómez, S. Dahiya, et al., “Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments,” Cell Metabolism 25, no. 6 (2017): 1282-1293.e7.

[24] H. Xia, W. Wang, J. Crespo, et al., “Suppression of FIP200 and Autophagy by Tumor-Derived Lactate Promotes Naïve T Cell Apoptosis and Affects Tumor Immunity,” Science Immunology 2, no. 17 (2017): eaan4631.

[25] G. Comito, A. Iscaro, M. Bacci, et al., “Lactate Modulates CD4+ T-Cell Polarization and Induces an Immunosuppressive Environment, Which Sustains Prostate Carcinoma Progression via TLR8/miR21 Axis,” Oncogene 38, no. 19 (2019): 3681-3695.

[26] V. Pucino, M. Certo, V. Bulusu, et al., “Lactate Buildup at the Site of Chronic Inflammation Promotes Disease by Inducing CD⁴⁺ T Cell Metabolic Rewiring,” Cell Metabolism 30, no. 6 (2019): 1055-1074.e8.

[27] W. Fan, X. Wang, S. Zeng, et al., “Global Lactylome Reveals Lactylation-Dependent Mechanisms Underlying T_H17 Differentiation in Experimental Autoimmune Uveitis,” Science Advances 9, no. 42 (2023): eadh4655.

[28] L. Chen, L. Huang, Y. Gu, W. Cang, P. Sun, and Y. Xiang, “Lactate-Lactylation Hands Between Metabolic Reprogramming and Immunosuppression,” International Journal of Molecular Sciences 23, no. 19 (2022): 11943.

[29] A. Brand, K. Singer, G. E. Gudrun, et al., “LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells,” Cell Metabolism 24, no. 5 (2016): 657-671.

[30] C. Harmon, M. W. Robinson, F. Hand, et al., “Lactate-Mediated Acidification of Tumor Microenvironment Induces Apoptosis of Liver-Resident NK Cells in Colorectal Liver Metastasis,” Cancer Immunology Research 7, no. 2 (2019): 335-346.

[31] G. Habif, A. Crinier, P. André, E. Vivier, and E. Narni-Mancinelli, “Targeting Natural Killer Cells in Solid Tumors,” Cellular & Molecular Immunology 16, no. 5 (2019): 415-422.

[32] I. Terrén, A. Orrantia, J. Vitallé, O. Zenarruzabeitia, and F. Borrego, “NK Cell Metabolism and Tumor Microenvironment,” Frontiers in Immunology 10 (2019): 2278.

[33] D. Raychaudhuri, R. Bhattacharya, B. P. Sinha, et al., “Lactate Induces Pro-Tumor Reprogramming in Intratumoral Plasmacytoid Dendritic Cells,” Frontiers in Immunology 10 (2019): 1878.

[34] O. R. Colegio, N.-Q. Chu, A. L. Szabo, et al., “Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid,” Nature 513, no. 7519 (2014): 559-563.

[35] K. Yang, J. Xu, M. Fan, et al., “Lactate Suppresses Macrophage Pro-Inflammatory Response to LPS Stimulation by Inhibition of YAP and NF-κB Activation via GPR81-Mediated Signaling,” Frontiers in Immunology 11 (2020): 587913.

[36] W. Li, T. Tanikawa, I. Kryczek, et al., “Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer,” Cell Metabolism 28, no. 1 (2018): 87-103.e6.

[37] T. P. Brown, P. Bhattacharjee, S. Ramachandran, et al., “The Lactate Receptor GPR81 Promotes Breast Cancer Growth via a Paracrine Mechanism Involving Antigen-Presenting Cells in the Tumor Microenvironment,” Oncogene 39, no. 16 (2020): 3292-3304.

[38] V. L. Payen, E. Mina, V. F. Van Hée, P. E. Porporato, and P. Sonveaux, “Monocarboxylate Transporters in Cancer,” Molecular Metabolism 33 (2020): 48-66.

[39] M. M. G. Kes, J. Van Den Bossche, A. W. Griffioen, and E. J. M. Huijbers, “Oncometabolites Lactate and Succinate Drive Pro-Angiogenic Macrophage Response in Tumors,” Biochimica Et Biophysica Acta (BBA)—Reviews on Cancer 1874, no. 2 (2020): 188427.

[40] J. Zhou, L. Zhang, J. Peng, et al., “Astrocytic LRP1 Enables Mitochondria Transfer to Neurons and Mitigates Brain Ischemic Stroke by Suppressing ARF1 Lactylation,” Cell Metabolism 36, no. 9 (2024): 2054-2068.e14.

[41] Q. Meng, H. Sun, Y. Zhang, et al., “Lactylation Stabilizes DCBLD1 Activating the Pentose Phosphate Pathway to Promote Cervical Cancer Progression,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 36.

[42] S. Kumagai, S. Koyama, K. Itahashi, et al., “Lactic Acid Promotes PD-1 Expression in Regulatory T Cells in Highly Glycolytic Tumor Microenvironments,” Cancer Cell 40, no. 2 (2022): 201-218.e9.

[43] N. Wan, N. Wang, S. Yu, et al., “Cyclic Immonium Ion of Lactyllysine Reveals Widespread Lactylation in the Human Proteome,” Nature Methods 19, no. 7 (2022): 854-864.

[44] R. Y. Pan, L. He, J. Zhang, et al., “Positive Feedback Regulation of Microglial Glucose Metabolism by Histone H4 Lysine 12 Lactylation in Alzheimer's Disease,” Cell Metabolism 34, no. 4 (2022): 634-648.

[45] J. Qiao, Y. Tan, H. Liu, et al., “Histone H3K18 and Ezrin Lactylation Promote Renal Dysfunction in Sepsis-Associated Acute Kidney Injury,” Advanced Science 11, no. 28 (2024): e2307216.

[46] X. Chu, C. Di, P. Chang, et al., “Lactylated Histone H3K18 as a Potential Biomarker for the Diagnosis and Predicting the Severity of Septic Shock,” Frontiers in Immunology 12 (2021): 786666.

[47] L. Wei, X. Yang, J. Wang, et al., “H3K18 Lactylation of Senescent Microglia Potentiates Brain Aging and Alzheimer's Disease Through the NFκB Signaling Pathway,” Journal of Neuroinflammation 20, no. 1 (2023): 208.

[48] W. Li, C. Zhou, L. Yu, et al., “Tumor-Derived Lactate Promotes Resistance to Bevacizumab Treatment by Facilitating Autophagy Enhancer Protein RUBCNL Expression Through Histone H3 Lysine 18 Lactylation (H3K18la) in Colorectal Cancer,” Autophagy 20, no. 1 (2024): 114-130.

[49] M. Dong, Y. Zhang, M. Chen, et al., “ASF1A-Dependent P300-Mediated Histone H3 Lysine 18 Lactylation Promotes Atherosclerosis by Regulating EndMT,” Acta Pharmaceutica Sinica B 14, no. 7 (2024): 3027-3048.

[50] J. Li, W. Hou, Q. Zhao, et al., “Lactate Regulates Major Zygotic Genome Activation by H3K18 Lactylation in Mammals,” National Science Review 11, no. 2 (2024): nwad295.

[51] P. Wang, D. Xie, T. Xiao, et al., “H3K18 Lactylation Promotes the Progression of Arsenite-Related Idiopathic Pulmonary Fibrosis via YTHDF1/m6A/NREP,” Journal of Hazardous Materials 461 (2024): 132582.

[52] X. Li, M. Chen, X. Chen, et al., “TRAP1 Drives Smooth Muscle Cell Senescence and Promotes Atherosclerosis via HDAC3-Primed Histone H4 Lysine 12 Lactylation,” European Heart Journal 45, no. 39 (2024): 4219-4235.

[53] Y. Wang, H. Li, S. Jiang, et al., “The Glycolytic Enzyme PFKFB3 Drives Kidney Fi Brosis Through Promoting Histone Lactylation-Mediated NF-kB k B Family Activation,” Kidney International 106, no. 2 (2024): 226-240.

[54] D. Yin, N. Jiang, C. Cheng, et al., “Protein Lactylation and Metabolic Regulation of the Zoonotic Parasite Toxoplasma gondii,” Genomics Proteomics & Bioinformatics 21, no. 6 (2023): 1163-1181.

[55] K. Yang, M. Fan, X. Wang, et al., “Lactate Promotes Macrophage HMGB1 Lactylation, Acetylation, and Exosomal Release in Polymicrobial Sepsis,” Cell Death and Differentiation 29, no. 1 (2022): 133-146.

[56] Z. Zong, F. Xie, S. Wang, et al., “Alanyl-tRNA Synthetase, AARS1, Is a Lactate Sensor and Lactyltransferase That Lactylates p53 and Contributes to Tumorigenesis,” Cell 187, no. 10 (2024): 2375-2392.e33.

[57] J. Ju, H. Zhang, M. Lin, et al., “The Alanyl-tRNA Synthetase AARS1 Moonlights as a Lactyltransferase to Promote YAP Signaling in Gastric Cancer,” Journal of Clinical Investigation 134, no. 10 (2024): e174587.

[58] H. Li, C. Liu, R. Li, et al., “AARS1 and AARS2 Sense L-Lactate to Regulate cGAS as Global Lysine Lactyltransferases,” Nature 634, no. 8036 (2024): 1229-1237.

[59] Z. Yang, C. Yan, J. Ma, et al., “Lactylome Analysis Suggests Lactylation-Dependent Mechanisms of Metabolic Adaptation in Hepatocellular Carcinoma,” Nature Metabolism 5, no. 1 (2023): 61-79.

[60] H. Dong, J. Zhang, H. Zhang, et al., “YiaC and CobB Regulate Lysine Lactylation in Escherichia coli,” Nature Communications 13, no. 1 (2022): 6628.

[61] M. Gao, N. Zhang, and W. Liang, “Systematic Analysis of Lysine Lactylation in the Plant Fungal Pathogen Botrytis cinerea,” Frontiers in Microbiology 11 (2020): 594743.

[62] X. Meng, J. M. Baine, T. Yan, and S. Wang, “Comprehensive Analysis of Lysine Lactylation in Rice (Oryza sativa) Grains,” Journal of Agricultural and Food Chemistry 69, no. 29 (2021): 8287-8297.

[63] D. An, L. Song, Y. Li, et al., “Comprehensive Analysis of Lysine Lactylation in Frankliniella Occidentalis,” Frontiers in Genetics 13 (2022): 1014225.

[64] D. Zhang, J. Gao, Z. Zhu, et al., “Lysine L-Lactylation is the Dominant Lactylation Isomer Induced by Glycolysis,” Nature Chemical Biology 21, no. 1 (2025): 91-99.

[65] C. Moreno-Yruela, D. Zhang, W. Wei, et al., “Class I Histone Deacetylases (HDAC1-3) Are Histone Lysine Delactylases,” Science Advances 8, no. 3 (2022): eabi6696.

[66] R. Du, Y. Gao, C. Yan, et al., “Sirtuin 1/sirtuin 3 Are Robust Lysine Delactylases and Sirtuin 1-Mediated Delactylation Regulates Glycolysis,” Iscience 27, no. 10 (2024): 110911.

[67] J. Jin, L. Bai, D. Wang, et al., “SIRT3-Dependent Delactylation of Cyclin E2 Prevents Hepatocellular Carcinoma Growth,” EMBO Reports 24, no. 5 (2023): e56052.

[68] Z. Fan, Z. Liu, N. Zhang, et al., “Identification of SIRT3 as an Eraser of H4K16la,” iScience 26, no. 10 (2023): 107757.

[69] H. Chen, Y. Li, H. Li, et al., “NBS1 Lactylation is Required for Efficient DNA Repair and Chemotherapy Resistance,” Nature 631, no. 8021 (2024): 663-669.

[70] S. Sun, Z. Xu, L. He, et al., “Metabolic Regulation of Cytoskeleton Functions by HDAC6-Catalyzed α-Tubulin Lactylation,” Nature Communications 15, no. 1 (2024): 8377.

[71] Y. Mao, J. Zhang, Q. Zhou, et al., “Hypoxia Induces Mitochondrial Protein Lactylation to Limit Oxidative Phosphorylation,” Cell Research 34, no. 1 (2024): 13-30.

[72] X. Hu, X. Huang, Y. Yang, et al., “Dux Activates Metabolism-Lactylation-MET Network During Early iPSC Reprogramming With Brg1 as the Histone Lactylation Reader,” Nucleic Acids Research 52, no. 10 (2024): 5529-5548.

[73] Z. Niu, C. Chen, S. Wang, et al., “HBO1 Catalyzes Lysine Lactylation and Mediates Histone H3K9la to Regulate Gene Transcription,” Nature Communications 15, no. 1 (2024): 3561.

[74] Q. Yan, J. Zhou, Y. Gu, et al., “Lactylation of NAT10 Promotes N4-Acetylcytidine Modification on tRNASer-CGA-1-1 to Boost Oncogenic DNA Virus KSHV Reactivation,” Cell Death & Differentiation 31, no. 10 (2024): 1362-1374.

[75] J. Wang, P. Yang, T. Yu, et al., “Lactylation of PKM2 Suppresses Inflammatory Metabolic Adaptation in Pro-Inflammatory Macrophages,” International Journal of Biological Sciences 18, no. 16 (2022): 6210-6225.

[76] J. Gu, J. Zhou, Q. Chen, et al., “Tumor Metabolite Lactate Promotes Tumorigenesis by Modulating MOESIN Lactylation and Enhancing TGF-β Signaling in Regulatory T Cells,” Cell Reports 39, no. 12 (2022): 110986.

[77] R. Zappasodi, I. Serganova, I. J. Cohen, et al., “CTLA-4 Blockade Drives Loss of Treg Stability in Glycolysis-Low Tumours,” Nature 591, no. 7851 (2021): 652-658.

[78] S. An, Y. Yao, H. Hu, et al., “PDHA1 Hyperacetylation-Mediated Lactate Overproduction Promotes Sepsis-Induced Acute Kidney Injury via Fis1 Lactylation,” Cell Death & Disease 14, no. 7 (2023): 457.

[79] S. Caielli, J. Cardenas, A. A. de Jesus, et al., “Erythroid Mitochondrial Retention Triggers Myeloid-Dependent Type I Interferon in Human SLE,” Cell 184, no. 17 (2021): 4464-4479.e19.

[80] J. Zhang, J. Zhang, H. Ji, et al., “Mitochondrial DNA Programs Lactylation of cGAS to Induce IFN Responses in Patients With Systemic Lupus Erythematosus,” Journal of Immunology 213, no. 6 (2024): 795-807.

[81] M. Fan, K. Yang, X. Wang, et al., “Lactate Promotes Endothelial-to-Mesenchymal Transition via Snail1 Lactylation After Myocardial Infarction,” Science Advances 9, no. 5 (2023): eadc9465.

[82] Y. Yao, R. Bade, G. Li, et al., “Global-Scale Profiling of Differential Expressed Lysine-Lactylated Proteins in the Cerebral Endothelium of Cerebral Ischemia-Reperfusion Injury Rats,” Cellular and Molecular Neurobiology 43, no. 5 (2023): 1989-2004.

[83] H. Rho, A. R. Terry, C. Chronis, and N. Hay, “Hexokinase 2-Mediated Gene Expression via Histone Lactylation is Required for Hepatic Stellate Cell Activation and Liver Fibrosis,” Cell Metabolism 35, no. 8 (2023): 1406-1423.e8.

[84] X. Lin, Y. Lei, M. Pan, et al., “Augmentation of Scleral Glycolysis Promotes Myopia Through Histone Lactylation,” Cell Metabolism 36, no. 3 (2024): 511-525.e7.

[85] W. Ma, K. Jia, H. Cheng, et al., “Orphan Nuclear Receptor NR4A3 Promotes Vascular Calcification via Histone Lactylation,” Circulation Research 134, no. 11 (2024): 1427-1447.

[86] N. Wang, W. Wang, X. Wang, et al., “Histone Lactylation Boosts Reparative Gene Activation Post-Myocardial Infarction,” Circulation Research 131, no. 11 (2022): 893-908.

[87] Y. Wang, L. Chen, M. Zhang, et al., “Exercise-Induced Endothelial Mecp2 Lactylation Suppresses Atherosclerosis via the Ereg/MAPK Signalling Pathway,” Atherosclerosis 375 (2023): 45-58.

[88] D. Yang, J. Yin, L. Shan, X. Yi, W. Zhang, and Y. Ding, “Identification of Lysine-Lactylated Substrates in Gastric Cancer Cells,” iScience 25, no. 7 (2022): 104630.

[89] X. Gu, A. Zhuang, J. Yu, et al., “Histone Lactylation-Boosted ALKBH3 Potentiates Tumor Progression and Diminished Promyelocytic Leukemia Protein Nuclear Condensates by M<SUP>1</SUP>a Demethylation of SP100A,” Nucleic Acids Research 52, no. 5 (2024): 2273-2289.

[90] J. Liao, Z. Chen, R. Chang, et al., “CENPA Functions as a Transcriptional Regulator to Promote Hepatocellular Carcinoma Progression via Cooperating With YY1,” International Journal of Biological Sciences 19, no. 16 (2023): 5218-5232.

[91] B. Chen, Y. Deng, Y. Hong, et al., “Metabolic Recoding of NSUN2-Mediated M(5)C Modification Promotes the Progression of Colorectal Cancer via the NSUN2/YBX1/m(5)C-ENO1 Positive Feedback Loop,” Advanced Science (Weinh) 11, no. 28 (2024): e2309840.

[92] Z. Qiao, Y. Li, S. Li, S. Liu, and Y. Cheng, “Hypoxia-Induced SHMT2 Protein Lactylation Facilitates Glycolysis and Stemness of Esophageal Cancer Cells,” Molecular and Cellular Biochemistry 479, no. 11 (2024): 3063-3076.

[93] X. Zou, X.-Y. Tang, Z.-Y. Qu, et al., “Targeting the PDGF/PDGFR Signaling Pathway for Cancer Therapy: A Review,” International Journal of Biological Macromolecules 202 (2022): 539-557.

[94] X. L. Huang, M. I. Khan, J. Wang, et al., “Role of Receptor Tyrosine Kinases Mediated Signal Transduction Pathways in Tumor Growth and Angiogenesis—New Insight and Futuristic Vision,” International Journal of Biological Macromolecules 180 (2021): 739-752.

[95] E. Cavalcanti, A. Ignazzi, F. De Michele, and M. L. Caruso, “PDGFRα Expression as a Novel Therapeutic Marker in Well-Differentiated Neuroendocrine Tumors,” Cancer Biology & Therapy 20, no. 4 (2019): 423-430.

[96] K. Balamurugan, L. Koehler, J.-N. Dürig, et al., “Structural Insights Into the Modulation of PDGF/PDGFR-β Complexation by Hyaluronan Derivatives,” Biological Chemistry 402, no. 11 (2021): 1441-1452.

[97] J. Yang, L. Luo, C. Zhao, et al., “A Positive Feedback Loop Between Inactive VHL-Triggered Histone Lactylation and PDGFRbeta Signaling Drives Clear Cell Renal Cell Carcinoma Progression,” International Journal of Biological Sciences 18, no. 8 (2022): 3470-3483.

[98] J. Yu, P. Chai, M. Xie, et al., “Histone Lactylation Drives Oncogenesis by Facilitating m6A Reader Protein YTHDF2 Expression in Ocular Melanoma,” Genome Biology 22, no. 1 (2021): 85.

[99] L. Pan, F. Feng, J. Wu, et al., “Demethylzeylasteral Targets Lactate by Inhibiting Histone Lactylation to Suppress the Tumorigenicity of Liver Cancer Stem Cells,” Pharmacological Research 181 (2022): 106270.

[100] J. Xiong, J. He, J. Zhu, et al., “Lactylation-Driven METTL3-Mediated RNA M(6)A Modification Promotes Immunosuppression of Tumor-Infiltrating Myeloid Cells,” Molecular Cell 82, no. 9 (2022): 1660-1677.e10.

[101] X. M. Li, Y. Yang, F. Q. Jiang, et al., “Histone Lactylation Inhibits RARgamma Expression in Macrophages to Promote Colorectal Tumorigenesis Through Activation of TRAF6-IL-6-STAT3 Signaling,” Cell Reports 43, no. 2 (2024): 113688.

[102] J. Zhou, W. Xu, Y. Wu, et al., “GPR37 Promotes Colorectal Cancer Liver Metastases by Enhancing the Glycolysis and Histone Lactylation via Hippo Pathway,” Oncogene 42, no. 45 (2023): 3319-3330.

[103] J. Wang, Z. Liu, Y. Xu, et al., “Enterobacterial LPS-Inducible LINC00152 Is Regulated by Histone Lactylation and Promotes Cancer Cells Invasion and Migration,” Frontiers in Cellular and Infection Microbiology 12 (2022): 913815.

[104] Z. Miao, X. Zhao, and X. Liu, “Hypoxia Induced Beta-Catenin Lactylation Promotes the Cell Proliferation and Stemness of Colorectal Cancer Through the wnt Signaling Pathway,” Experimental Cell Research 422, no. 1 (2023): 113439.

[105] B. Xie, M. Zhang, J. Li, et al., “KAT8-Catalyzed Lactylation Promotes eEF1A2-Mediated Protein Synthesis and Colorectal Carcinogenesis,” PNAS 121, no. 8 (2024): e2314128121.

[106] Y. Zhao, Y. He, Z. Xiao, et al., “circEIF3I Promotes Colorectal Cancer Metastasis by Regulating the miR-328-3p/NCAPH Axis,” Molecular Carcinogenesis 64, no. 3 (2025): 450-462.

[107] J. Jiang, D. Huang, Y. Jiang, et al., “Lactate Modulates Cellular Metabolism Through Histone Lactylation-Mediated Gene Expression in Non-Small Cell Lung Cancer,” Frontiers in Oncology 11 (2021): 647559.

[108] L. Sun, Y. Zhang, B. Yang, et al., “Lactylation of METTL16 Promotes Cuproptosis via m6A-Modification on FDX1 mRNA in Gastric Cancer,” Nature Communications 14, no. 1 (2023): 6523.

[109] F. Li, W. Si, L. Xia, et al., “Positive Feedback Regulation Between Glycolysis and Histone Lactylation Drives Oncogenesis in Pancreatic Ductal Adenocarcinoma,” Molecular Cancer 23, no. 1 (2024): 90.

[110] G. Li, D. Wang, Y. Zhai, et al., “Glycometabolic Reprogramming-Induced XRCC1 Lactylation Confers Therapeutic Resistance in ALDH1A3-Overexpressing Glioblastoma,” Cell Metabolism 36, no. 8 (2024): 1696-1710.e10.

[111] Q. Yue, Z. Wang, Y. Shen, et al., “Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2-Mediated MLH1 Intron Retention,” Advanced Science 11, no. 19 (2024): e2309290.

[112] R. Zhu, X. Ye, X. Lu, et al., “ACSS2 Acts as a Lactyl-CoA Synthetase and Couples KAT2A to Function as a Lactyltransferase for Histone Lactylation and Tumor Immune Evasion,” Cell Metabolism 37, no. 2 (2025): 361-376.e7.

[113] L. Yang, K. Niu, J. Wang, et al., “Nucleolin Lactylation Contributes to Intrahepatic Cholangiocarcinoma Pathogenesis via RNA Splicing Regulation of MADD,” Journal of Hepatology 81, no. 4 (2024): 651-666.

[114] F. Li, H. Zhang, Y. Huang, et al., “Single-Cell Transcriptome Analysis Reveals the Association Between Histone Lactylation and Cisplatin Resistance in Bladder Cancer,” Drug Resistance Updates 73 (2024): 101059.

[115] B. Xie, J. Lin, X. Chen, et al., “CircXRN2 Suppresses Tumor Progression Driven by Histone Lactylation Through Activating the Hippo Pathway in Human Bladder Cancer,” Molecular Cancer 22, no. 1 (2023): 151.

[116] D. Wang, G. Du, X. Chen, et al., “Zeb1-Controlled Metabolic Plasticity Enables Remodeling of Chromatin Accessibility in the Development of Neuroendocrine Prostate Cancer,” Cell Death & Differentiation 31, no. 6 (2024): 779-791.

[117] Q. Meng, Y. Zhang, H. Sun, et al., “Human Papillomavirus-16 E6 Activates the Pentose Phosphate Pathway to Promote Cervical Cancer Cell Proliferation by Inhibiting G6PD Lactylation,” Redox Biology 71 (2024): 103108.

[118] F. Jing, L. Zhu, J. Zhang, et al., “Multi-Omics Reveals Lactylation-Driven Regulatory Mechanisms Promoting Tumor Progression in Oral Squamous Cell Carcinoma,” Genome Biology 25, no. 1 (2024): 272.

[119] X. Hou, J. Ouyang, L. Tang, et al., “KCNK1 Promotes Proliferation and Metastasis of Breast Cancer Cells by Activating Lactate Dehydrogenase A (LDHA) and Up-Regulating H3K18 Lactylation,” PLOS Biology 22, no. 6 (2024): e3002666.

[120] M. R. Pandkar, S. Sinha, A. Samaiya, and S. Shukla, “Oncometabolite Lactate Enhances Breast Cancer Progression by Orchestrating Histone Lactylation-Dependent c-Myc Expression,” Translational Oncology 37 (2023): 101758.

[121] Y. Luo, Z. Yang, Y. Yu, and P. Zhang, “HIF1α Lactylation Enhances KIAA1199 Transcription to Promote Angiogenesis and Vasculogenic Mimicry in Prostate Cancer,” International Journal of Biological Macromolecules 222 (2022): 2225-2243.

[122] Y.-D. Chu, L.-C. Cheng, S.-N. Lim, M.-W. Lai, C.-T. Yeh, and W.-R. Lin, “Aldolase B-Driven Lactagenesis and CEACAM6 Activation Promote Cell Renewal and Chemoresistance in Colorectal Cancer Through the Warburg Effect,” Cell Death & Disease 14, no. 10 (2023): 660.

[123] X. Sun, L. He, H. Liu, et al., “The Diapause-Like Colorectal Cancer Cells Induced by SMC4 Attenuation Are Characterized by Low Proliferation and Chemotherapy Insensitivity,” Cell Metabolism 35, no. 9 (2023): 1563-1579.e8.

[124] R. Liu, X. Ren, Y. E. Park, et al., “Nuclear GTPSCS Functions as a Lactyl-CoA Synthetase to Promote Histone Lactylation and Gliomagenesis,” Cell Metabolism 37, no. 2 (2025): 377-394.e9.

[125] J. Huang, X. Wang, N. Li, et al., “YY1 Lactylation Aggravates Autoimmune Uveitis by Enhancing Microglial Functions via Inflammatory Genes,” Advanced Science (Weinh) 11, no. 19 (2024): e2308031.

[126] F. Merkuri, M. Rothstein, and M. Simoes-Costa, “Histone Lactylation Couples Cellular Metabolism With Developmental Gene Regulatory Networks,” Nature Communications 15, no. 1 (2024): 90.

[127] S. Daneshmandi, B. Wegiel, and P. Seth, “Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma,” Cancers 11, no. 4 (2019): 450.

[128] T. Cascone, J. A. McKenzie, R. M. Mbofung, et al., “Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy,” Cell Metabolism 27, no. 5 (2018): 977-987.e4.

[129] J. Gu, J. Zhou, and L. Lu, “1810P Tumor Metabolite Lactate Promotes Tumorigenesis Through Modulating Moesin Lactylation and TGF-b Signaling of Regulatory T Cells,” Annals of Oncology 32, no. Supplement 5 (2021): S1230S.

[130] M. Beloueche-Babari, T. Casals Galobart, T. Delgado-Goni, et al., “Monocarboxylate Transporter 1 Blockade With AZD3965 Inhibits Lipid Biosynthesis and Increases Tumour Immune Cell Infiltration,” British Journal of Cancer 122, no. 6 (2020): 895-903.

[131] M. Yang, X. Zhong, and Y. Yuan, “Does Baking Soda Function as a Magic Bullet for Patients With Cancer? A Mini Review,” Integrative Cancer Therapies 19 (2020): 153473542092257.

[132] J. Tang, J. X. Yu, V. M. Hubbard-Lucey, S. T. Neftelinov, J. P. Hodge, and Y. Lin, “The Clinical Trial Landscape for PD1/PDL1 Immune Checkpoint Inhibitors,” Nature Reviews Drug Discovery 17, no. 12 (2018): 854-855.

[133] Y. Chen, J. Wu, L. Zhai, et al., “Metabolic Regulation of Homologous Recombination Repair by MRE11 Lactylation,” Cell 187, no. 2 (2024): 294-311.e21.

[134] Y. Zhang and X. Zhang, “Virus-Induced Histone Lactylation Promotes Virus Infection in Crustacean,” Advanced Science 11, no. 30 (2024): e2401017.

[135] D. Wu, C. B. Spencer, L. Ortoga, H. Zhang, and C. Miao, “Histone Lactylation-Regulated METTL3 Promotes Ferroptosis via m6A-Modification on ACSL4 in Sepsis-Associated Lung Injury,” Redox Biology 74 (2024): 103194.

[136] A. De Leo, A. Ugolini, X. Yu, et al., “Glucose-Driven Histone Lactylation Promotes the Immunosuppressive Activity of Monocyte-Derived Macrophages in Glioblastoma,” Immunity 57, no. 5 (2024): 1105-1123.e8.

[137] H. Ren, Z. Wu, J. Tan, et al., “Co-Delivery Nano System of MS-275 and V-9302 Induces Pyroptosis and Enhances Anti-Tumor Immunity Against Uveal Melanoma,” Advanced Science (Weinh) 11, no. 31 (2024): e2404375.

[138] B. Liao, Q. Sun, Y. Yuan, Y. Yin, J. Qiao, and P. Jiang, “Histone Deacetylase Inhibitor MGCD0103 Causes Cell Cycle Arrest, Apoptosis, and Autophagy in Liver Cancer Cells,” Journal of Cancer 11, no. 7 (2020): 1915-1926.

[139] R. Huang, X. Zhang, Z. Min, A. S. Shadia, S. E. Yang, and X. Liu, “MGCD0103 Induces Apoptosis and Simultaneously Increases the Expression of NF‑κB and PD‑L1 in Classical Hodgkin's Lymphoma,” Experimental and Therapeutic Medicine 16, no. 5 (2018): 3827-3834.

[140] X. Dai, X. Lv, E. W. Thompson, and K. K. Ostrikov, “Histone Lactylation: Epigenetic Mark of Glycolytic Switch,” Trends in Genetics 38, no. 2 (2022): 124-127.

[141] D. Benjamin, D. Robay, S. K. Hindupur, et al., “Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal With Metformin due to NAD+ Depletion in Cancer Cells,” Cell Reports 25, no. 11 (2018): 3047-3058.e4.

[142] S. Halford, G. J. Veal, S. R. Wedge, et al., “A Phase I Dose-Escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients With Advanced Cancer,” Clinical Cancer Research 29, no. 8 (2023): 1429-1439.

[143] X. Guan and M. E. Morris, “In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model,” AAPS Journal 22, no. 4 (2020): 84.

[144] E. Lopez, R. Karattil, F. Nannini, et al., “Inhibition of Lactate Transport by MCT-1 Blockade Improves Chimeric Antigen Receptor T-Cell Therapy Against B-Cell Malignancies,” Journal for ImmunoTherapy of Cancer 11, no. 6 (2023): e006287.

[145] E. M. E. Barnes, Y. Xu, A. Benito, et al., “Lactic Acidosis Induces Resistance to the pan-Akt Inhibitor Uprosertib in Colon Cancer Cells,” British Journal of Cancer 122, no. 9 (2020): 1298-1308.

[146] A. Yamaguchi, Y. Mukai, T. Sakuma, et al., “Monocarboxylate Transporter 4 Involves in Energy Metabolism and Drug Sensitivity in Hypoxia,” Scientific Reports 13, no. 1 (2023): 1501.

[147] X. Guan, V. Rodriguez-Cruz, and M. E. Morris, “Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells,” AAPS Journal 21, no. 2 (2019): 13.

[148] C. Corbet, E. Bastien, N. Draoui, et al., “Interruption of Lactate Uptake by Inhibiting Mitochondrial Pyruvate Transport Unravels Direct Antitumor and Radiosensitizing Effects,” Nature Communications 9, no. 1 (2018): 1208.

[149] C. Vander Linden, C. Corbet, E. Bastien, et al., “Therapy-Induced DNA Methylation Inactivates MCT1 and Renders Tumor Cells Vulnerable to MCT4 Inhibition,” Cell Reports 35, no. 9 (2021): 109202.

[150] C. Huang, X. Y. Dai, J. X. Cai, et al., “A Screened GPR1 Peptide Exerts Antitumor Effects on Triple-Negative Breast Cancer,” Molecular Therapy Oncolytics 18 (2020): 602-612.

[151] J. R. Doherty, C. Yang, K. E. N. Scott, et al., “Blocking Lactate Export by Inhibiting the Myc Target MCT1 Disables Glycolysis and Glutathione Synthesis,” Cancer Research 74, no. 3 (2014): 908-920.

[152] A. Khan, E. Valli, H. Lam, et al., “Targeting Metabolic Activity in High-Risk Neuroblastoma Through Monocarboxylate Transporter 1 (MCT1) Inhibition,” Oncogene 39, no. 17 (2020): 3555-3570.

[153] M. Ždralević, M. Vučetić, B. Daher, I. Marchiq, S. K. Parks, and J. Pouysségur, “Disrupting the ‘Warburg Effect’ Re-Routes Cancer Cells to OXPHOS Offering a Vulnerability Point via ‘Ferroptosis’-Induced Cell Death,” Advances in Biological Regulation 68 (2018): 55-63.

[154] N. Li, Y. Kang, L. Wang, et al., “ALKBH5 Regulates Anti-PD-1 Therapy Response by Modulating Lactate and Suppressive Immune Cell Accumulation in Tumor Microenvironment,” PNAS 117, no. 33 (2020): 20159-20170.

[155] W. Li, S. Liu, Y. Zhang, et al., “Dual-Inhibition of Lactate Metabolism and Prussian Blue-Mediated Radical Generation for Enhanced Chemodynamic Therapy and Antimetastatic Effect,” Nanoscale 15, no. 20 (2023): 9214-9228.

[156] B. Pajak, E. Siwiak, M. Soltyka, et al., “2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents,” International Journal of Molecular Sciences 21, no. 1 (2019): 234.

[157] Y. Zhou, M. Ran, W. Shan, K. Wang, O. Sha, and K. Y. Tam, “Targeting Hexokinase 2 to Enhance Anticancer Efficacy of Trichosanthin in HeLa and SCC25 Cell Models,” ADMET and DMPK 12, no. 6 (2024): 821-841.

[158] W. Li, M. Zheng, S. Wu, et al., “Benserazide, a Dopadecarboxylase Inhibitor, Suppresses Tumor Growth by Targeting Hexokinase 2,” Journal of Experimental & Clinical Cancer Research 36, no. 1 (2017): 58.

[159] D. J. Kim, M. T. Vo, S. H. Choi, et al., “Tristetraprolin-Mediated Hexokinase 2 Expression Regulation Contributes to Glycolysis in Cancer Cells,” Molecular Biology of the Cell 30, no. 5 (2019): 542-553.

[160] M. X. An, S. Li, H. B. Yao, et al., “BAG3 Directly Stabilizes Hexokinase 2 mRNA and Promotes Aerobic Glycolysis in Pancreatic Cancer Cells,” Journal of Cell Biology 216, no. 12 (2017): 4091-4105.

[161] M. Zheng, C. Wu, K. Yang, et al., “Novel Selective Hexokinase 2 Inhibitor Benitrobenrazide Blocks Cancer Cells Growth by Targeting Glycolysis,” Pharmacological Research 164 (2021): 105367.

[162] S. H. Jiang, F. Y. Dong, L. T. Da, et al., “Ikarugamycin Inhibits Pancreatic Cancer Cell Glycolysis by Targeting Hexokinase 2,” FASEB Journal 34, no. 3 (2020): 3943-3955.

[163] S. F. Powell, M. Mazurczak, E. G. Dib, et al., “Phase II Study of Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase, in Combination With Chemoradiotherapy for Unresected, Locally Advanced Head and Neck Squamous Cell Carcinoma,” Investigational New Drugs 40, no. 3 (2022): 622-633.

[164] H. Wu, Y. Wang, M. Ying, C. Jin, J. Li, and X. Hu, “Lactate Dehydrogenases Amplify Reactive Oxygen Species in Cancer Cells in Response to Oxidative Stimuli,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 242.

[165] X. Lv, Y. Lv, and X. Dai, “Lactate, Histone Lactylation and Cancer Hallmarks,” Expert Reviews in Molecular Medicine 25 (2023): e7.

[166] Y. Yang, Y. Chong, M. Chen, et al., “Targeting Lactate Dehydrogenase a Improves Radiotherapy Efficacy in Non-Small Cell Lung Cancer: From Bedside to Bench,” Journal of Translational Medicine 19, no. 1 (2021): 170.

[167] T. Qiao, Y. Xiong, Y. Feng, et al., “Inhibition of LDH-A by Oxamate Enhances the Efficacy of Anti-PD-1 Treatment in an NSCLC Humanized Mouse Model,” Frontiers in Oncology 11 (2021): 632364.

[168] Z. X. Meng, X. S. Zhang, H. Y. Tan, and H. Lian, “Zinc-Enriched Nanosystem for Dual Glycolysis Regulation and Photothermal Therapy to Synergistically Inhibit Primary Melanoma and Lung Metastasis,” Chemical Engineering Journal (2022): 435134781.

[169] M. Apicella, E. Giannoni, S. Fiore, et al., “Increased Lactate Secretion by Cancer Cells Sustains Non-Cell-Autonomous Adaptive Resistance to MET and EGFR Targeted Therapies,” Cell Metabolism 28, no. 6 (2018): 848-865.e6.

[170] L. Shi, R. Duan, Z. Sun, et al., “LncRNA GLTC Targets LDHA for Succinylation and Enzymatic Activity to Promote Progression and Radioiodine Resistance in Papillary Thyroid Cancer,” Cell Death and Differentiation 30, no. 6 (2023): 1517-1532.

[171] N. Oshima, R. Ishida, S. Kishimoto, et al., “Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid in Vivo Metabolic Rewiring and Vulnerability to Combination Therapy,” Cell Reports 30, no. 6 (2020): 1798-1810.e4.

[172] N. Sun, M. Kabir, Y. Lee, et al., “Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer,” Journal of Medicinal Chemistry 66, no. 1 (2023): 596-610.

[173] Z. Cao, D. Xu, J. Harding, et al., “Lactate Oxidase Nanocapsules Boost T Cell Immunity and Efficacy of Cancer Immunotherapy,” Science Translational Medicine 15, no. 717 (2023): eadd2712.

[174] J. Zhou, Y. Hu, Y. Cao, et al., “A Lactate-Depleting Metal Organic Framework-Based Nanocatalyst Reinforces Intratumoral T Cell Response to Boost Anti-PD1 Immunotherapy,” Journal of Colloid & Interface Science 660 (2024): 869-884.

[175] X. Zheng, Y. Liu, Y. Liu, et al., “Dual Closed-Loop of Catalyzed Lactate Depletion and Immune Response to Potentiate Photothermal Immunotherapy,” ACS Applied Materials & Interfaces 14, no. 20 (2022): 23260-23276.

[176] S. Zhao, H. Li, R. Liu, et al., “Nitrogen-Centered Lactate Oxidase Nanozyme for Tumor Lactate Modulation and Microenvironment Remodeling,” Journal of the American Chemical Society 145, no. 18 (2023): 10322-10332.

[177] G. Lu, X. Wang, F. Li, et al., “Engineered Biomimetic Nanoparticles Achieve Targeted Delivery and Efficient Metabolism-Based Synergistic Therapy Against Glioblastoma,” Nature Communications 13, no. 1 (2022): 4214.

[178] J. Zhao, Z. Tian, S. Zhao, et al., “Insights Into the Effect of Catalytic Intratumoral Lactate Depletion on Metabolic Reprogramming and Immune Activation for Antitumoral Activity,” Advanced Science (Weinh) 10, no. 4 (2023): e2204808.

[179] Y. Li, Y. Wei, Y. Huang, et al., “Lactate-Responsive Gene Editing to Synergistically Enhance Macrophage-Mediated Cancer Immunotherapy,” Small 19, no. 35 (2023): e2301519.

[180] X. Luo, J. Cao, J. Yu, et al., “Regulating Acidosis and Relieving Hypoxia by Platelet Membrane-Coated Nanoparticle for Enhancing Tumor Chemotherapy,” Frontiers in Bioengineering and Biotechnology 10 (2022): 885105.

[181] J. Tang, A. K. Meka, S. Theivendran, et al., “Openwork@Dendritic Mesoporous Silica Nanoparticles for Lactate Depletion and Tumor Microenvironment Regulation,” Angewandte Chemie (International ed in English) 59, no. 49 (2020): 22054-22062.

[182] Z. Zhang, B. Li, L. Xie, et al., “Metal-Phenolic Network-Enabled Lactic Acid Consumption Reverses Immunosuppressive Tumor Microenvironment for Sonodynamic Therapy,” ACS Nano 15, no. 10 (2021): 16934-16945.

[183] Z. Tian, K. Yang, T. Yao, et al., “Catalytically Selective Chemotherapy From Tumor-Metabolic Generated Lactic Acid,” Small 15, no. 46 (2019): e1903746.

[184] Q. Dong, C. Zhou, H. Ren, et al., “Lactate-Induced MRP1 Expression Contributes to Metabolism-Based Etoposide Resistance in Non-Small Cell Lung Cancer Cells,” Cell Communication and Signaling 18, no. 1 (2020): 167.

[185] S. F. Lam, K. W. Bishop, R. Mintz, L. Fang, and S. Achilefu, “Calcium Carbonate Nanoparticles Stimulate Cancer Cell Reprogramming to Suppress Tumor Growth and Invasion in an Organ-On-A-Chip System,” Scientific Reports 11, no. 1 (2021): 9246.

[186] Y. Yao, R. Xu, W. Shao, et al., “A Novel Nanozyme to Enhance Radiotherapy Effects by Lactic Acid Scavenging, ROS Generation, and Hypoxia Mitigation,” Advanced Science 11, no. 26 (2024): e2403107.

[187] T. Li, D. Xu, Z. Ruan, et al., “Metabolism/Immunity Dual-Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate-Excretion Inhibition and PD-1/PD-L1 Blockade,” Advanced Science 11, no. 18 (2024): e2310163.

[188] Y. Luo, Y. Li, Z. Huang, et al., “A Nanounit Strategy Disrupts Energy Metabolism and Alleviates Immunosuppression for Cancer Therapy,” Nano Letters 22, no. 15 (2022): 6418-6427.

[189] R. Niu, Y. Liu, B. Xu, et al., “Programmed Targeting Pyruvate Metabolism Therapy Amplified Single-Atom Nanozyme-Activated Pyroptosis for Immunotherapy,” Advanced Materials 36, no. 24 (2024): e2312124.

[190] H. Xu, L. Li, S. Wang, et al., “Royal Jelly Acid Suppresses Hepatocellular Carcinoma Tumorigenicity by Inhibiting H3 Histone Lactylation at H3K9la and H3K14la Sites,” Phytomedicine 118 (2023): 154940.

[191] P. Sun, L. Ma, and Z. Lu, “Lactylation: Linking the Warburg Effect to DNA Damage Repair,” Cell Metabolism 36, no. 8 (2024): 1637-1639.

[192] J. Chen, D. Zhao, Y. Wang, et al., “Lactylated Apolipoprotein C-II Induces Immunotherapy Resistance by Promoting Extracellular Lipolysis,” Advanced Science 11, no. 38 (2024): e2406333.

[193] R. Zhou, R.-C. Ding, Q. Yu, et al., “Metformin Attenuates Neutrophil Recruitment Through the H3K18 Lactylation/Reactive Oxygen Species Pathway in Zebrafish,” Antioxidants 13, no. 2 (2024): 176.

[194] Y. Fang, W. Liu, Z. Tang, et al., “Monocarboxylate Transporter 4 Inhibition Potentiates Hepatocellular Carcinoma Immunotherapy Through Enhancing T Cell Infiltration and Immune Attack,” Hepatology 77, no. 1 (2023): 109-123.

[195] F. Feng J. Wu, Q. Chi, et al., “Lactylome Analysis Unveils Lactylation-Dependent Mechanisms of Stemness Remodeling in the Liver Cancer Stem Cells,” Advanced Science 11, no. 38 (2024): e2405975.

[196] S. Han, X. Bao, Y. Zou, et al., “d-Lactate Modulates M2 Tumor-Associated Macrophages and Remodels Immunosuppressive Tumor Microenvironment for Hepatocellular Carcinoma,” Science Advances 9, no. 29 (2023): eadg2697.

[197] Y. Sun, Y. Chen, and T. Peng, “A Bioorthogonal Chemical Reporter for the Detection and Identification of Protein Lactylation,” Chemical Science 13, no. 20 (2022): 6019-6027.

[198] M. S. Oh, K. R. Phelps, M. Traube, J. L. Barbosa-Saldivar, C. Boxhill, and H. J. Carroll, “D-Lactic Acidosis in a Man With the Short-Bowel Syndrome,” New England Journal of Medicine 301, no. 5 (1979): 249-252.

[199] A. D. Hingorani and N. N. Chan, “D-Lactate Encephalopathy,” Lancet 358, no. 9295 (2001): 1814.

[200] H. Tong, Z. Jiang, L. Song, et al., “Dual Impacts of Serine/Glycine-Free Diet in Enhancing Antitumor Immunity and Promoting Evasion via PD-L1 Lactylation,” Cell Metabolism 36, no. 12 (2024): 2493-2510.e9.

[201] A. Silva, B. Antunes, A. Batista, F. Pinto-Ribeiro, F. Baltazar, and J. Afonso, “In Vivo Anticancer Activity of AZD3965: A Systematic Review,” Molecules 27, no. 1 (2021): 181.

[202] R. McNeillis, A. Greystoke, J. Walton, et al., “A Case of Malignant Hyperlactaemic Acidosis Appearing Upon Treatment With the Mono-Carboxylase Transporter 1 Inhibitor AZD3965,” British Journal of Cancer 122, no. 8 (2020): 1141-1145.

[203] P. A. Philip, M. E. Buyse, A. T. Alistar, et al., “A Phase III Open-Label Trial to Evaluate Efficacy and Safety of CPI-613 Plus Modified FOLFIRINOX (mFFX) Versus FOLFIRINOX (FFX) in Patients With Metastatic Adenocarcinoma of the Pancreas,” Future Oncology 15, no. 28 (2019): 3189-3196.

[204] A. Mohan, K. A. Griffith, F. Wuchu, et al., “Devimistat in Combination With Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04),” Clinical Cancer Research 29, no. 13 (2023): 2394-2400.

[205] R. Anderson, L. D. Miller, S. Isom, et al., “Phase II Trial of Cytarabine and Mitoxantrone With Devimistat in Acute Myeloid Leukemia,” Nature Communications 13, no. 1 (2022): 1673.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.